ClinicalTrials.gg

Program

R2R01

Its studies are mostly in Heart Failure · Acute Kidney Injury · Hepatorenal Syndrome, led by River 2 Renal.

Furthest: phase 2, since May 1, 20233 company-led studies, 2 open or runningNext primary completion: Apr 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
River 2 Renal32 open or runningphase 2since May 1, 2023May 1, 2023Apr 1, 2027phase 2 · NCT07625553

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 1, 2023First study: phase 2 study in Hepatorenal SyndromeFirst studyNCT05875948 · 95 planned · United States
  2. Jan 31, 2024Phase 2 study in Heart FailureNCT06264310 · 33 enrolled · United States
  3. Apr 24, 2026Phase 2 study in Acute Kidney InjuryNCT07625553 · 430 planned · Italy

Ahead

  1. Apr 1, 2027Primary completion: phase 2 study in Acute Kidney InjuryNCT07625553

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07625553Acute Kidney Injury · Italy2RecruitingApr 1, 2027430
NCT06264310Heart Failure · United States2CompletedNov 4, 202433
NCT05875948Hepatorenal Syndrome · United States2RecruitingDec 202495

How it is read

Names in the registry

  • “R2R01”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
R2R01 (River 2 Renal): development program | ClinicalTrials.gg